Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Jacob Johnson
Period: Reporting periods mapped to calendar 2024 Q3 – 2024 Q4 (2 quarters).
- Questions
- 8on tracked calls
- Challenge rate
- 13%1 of 8 questionsLimited sample
- Companies
- 4questioned at least once
- Reporting periods
- 2with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 8 of 8 questions from 4 companies
STESteris4 questions · 2 reporting periods · 1 of 4 challenging
Calendar 2024 Q4
Do you think this is what you're seeing in Healthcare Capital Equipment is just related to timing of orders? Is it kind of specific to 3Q
Show response
Dan confirmed strong underlying demand with orders coming in but customers pushing delivery timelines back. He could not definitively call it a trend yet.
could unpack the trends you're seeing in that bioprocessing end market and what that could mean as we look out over for AST
Show response
Dan expressed optimism that the bioprocessing destocking reset is complete, noting Q2-Q3 last year was the trough and the business should return to normalized growth.
Calendar 2024 Q3
I heard you mention no longer exiting the year at double digits for AST, but then it seems like maybe some positive bioprocessing commentary
Show response
Dan acknowledged medtech volumes are below expectations midyear but expressed optimism on bioprocessing; adjusted exit rate target to be more conservative.
can you frame up the magnitude of that loss, just how much of a headwind that was to margins in the segment
Show response
Mike Tokich directly quantified the 200bps margin impact and acknowledged the loss was larger than expected but characterized it as a onetime event.
TECHBio-Techne2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2024 Q3
Can you just talk about how Wilson Wolf trended in the quarter and any benefit on the other income line from them
Show response
Kim confirmed Wilson Wolf grew over 30% but Jim declined to give specifics on income contribution, noting FX translation from cash pooling was also a big chunk.
can you just help us think through kind of any one-time items in one queue and then any benefits from cost savings as we get into the rest of the year?
Show response
Jim explained Q2 will face larger incentive comp headwind plus merit increase timing, but maintained overall half-year margin guidance. Back-half margin expansion tied to revenue recovery.
CRLCharles River Laboratories1 question · 1 reporting period · 0 of 1 challenging
Calendar 2024 Q4
Is that something that is contemplated in the 1% headwind from the loss of those customers?
Show response
Flavia confirmed contractual obligations embedded in the 1% headwind. James acknowledged losing commercial clients isn't helpful for sales but said CDMO capabilities have been significantly enhanced.
WSTWest Pharmaceutical Services1 question · 1 reporting period · 0 of 1 challenging
Calendar 2024 Q4
Was this kind of a deliberate change in strategy that happened at some point, or is this just opportunistic
Show response
Eric confirmed deliberate shift toward drug device assembly and higher-value capabilities downstream, targeting mid-single-digit growth for contract manufacturing.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| STE Steris | 4 | 25%1 of 4 questions |
| TECH Bio-Techne | 2 | —Rate withheld: fewer than 3 questions |
| CRL Charles River Laboratories | 1 | —Rate withheld: fewer than 3 questions |
| WST West Pharmaceutical Services | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 4 | 25%1 of 4 questions | 2 |
| 2024 Q4 | 4 | 0%none of 4 questions | 3 |
- 2024 Q34 questions · challenge rate 25% (1 of 4 questions) · 2 companies
- 2024 Q44 questions · challenge rate 0% (none of 4 questions) · 3 companies
Topics
Topics tagged on this analyst’s questions.
- Demand4
- Revenue Growth4
- Margin2
- Cost Pressure2
- M&A2
- Capital Allocation1
- Competitive Dynamics1